Oxaliplatin, Paclitaxel, and Tislelizumab
About
Membership operator: AND
Therapies: 3
Therapies
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy group.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| EMA (1) | PD-L1 (TAP) >= 5% | Esophageal Squamous Cell Carcinoma | Oxaliplatin, Paclitaxel, Tislelizumab | |
| FDA (2) | PD-L1 (TAP) >= 1% | Esophageal Squamous Cell Carcinoma | Oxaliplatin, Paclitaxel, Tislelizumab | |
| FDA (2) | PD-L1 (CPS) >= 1 | Esophageal Squamous Cell Carcinoma | Oxaliplatin, Paclitaxel, Tislelizumab |